Skip to main content

Sports Anthony Joshua’s U.S. debut in doubt after opponent Jarrell Miller fails drug test

Anthony Joshua and Jarrell Miller square up at a promotional event at Hilton London Syon Park on Feb. 25, 2019 in London.

Richard Heathcote/Getty Images

Anthony Joshua’s debut fight in the United States could be in doubt after his promoter said the world heavyweight champion’s opponent has failed a doping test.

Eddie Hearn says in a Twitter post that Joshua’s camp has been informed by the Voluntary Anti-Doping Association that there was an adverse finding in a sample collected from American boxer Jarrell Miller on March 20.

Hearn says “we are working with all relevant parties and will update with more details soon.”

Story continues below advertisement

Salita Promotions, which represents Miller, said Wednesday it was obtaining more information about VADA’s finding and “will have more to say soon on this developing situation.”

Joshua, who holds the WBA, IBF, WBO and IBO belts, is scheduled to fight Miller on June 1 at Madison Square Garden.

During the promotional tour for the fight, Miller said both fighters had agreed to between 10 and 12 weeks of drug testing in the buildup to the bout.

Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Discussion loading ...

Cannabis pro newsletter